Xu Bing, Hu Cheng, Miao Xu-dong, Wu Yan-hong, Yi Zheng-shan, Yang Yi, Meng Fan-yi, Feng Ru, Liu Qi-fa, Liu Xiao-li, Zheng Wei-yang
Department of Hematology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China.
Di Yi Jun Yi Da Xue Xue Bao. 2003 Oct;23(10):1043-6.
To study the immunophenotyping of adult patients with acute leukemia and its association with the prognosis.
Immunophenotyping was performed in 106 adult patients with acute leukemia by three-color flow cytometry analysis using CD34/SSC gating.
The antigens expressed in 71 patients with acute myeloid leukemia (AML) were mainly CD13, CD33, HLA-DR, CD34 and CD117. Lymphoid antigen expression was identified in 23.9% adult AML patients and CD56 antigen expression in 15.5% of the AML patients. In 29 patients with acute lymphoblastic leukemia (ALL), the expressed antigens were mainly HLA-DR, CD10, CD19, CD34 and CD7, and 34.5% of these patients were found to be positive for myeloid antigen expression. Complete remission (CR) rate in AML patients with lymphoid antigen expression after chemotherapy was lower than that in AML patients without lymphoid antigen expression (52.9% vs 77.8%, P<0.05), and no significant impact was noted of myeloid antigen expression in ALL on the CR of the patients (70.0% vs 94.7%, P>0.05). The CR rate in AML with CD56 antigen expression was lower than that in AML without CD56 expression (36.4% vs 78.3%, P<0.025), and the CR rate in CD34+ AML was lower than that in CD34- AML (56.0% vs 80.4%, P<0.05).
Gating of CD45/SSC can eliminate the interference of normal cells to render more reliable immunophenotyping results. The expressions of CD56+, CD34+, lymphoid antigen in adult AML patients, who have lower CR rate, often signify poor prognosis.
研究成年急性白血病患者的免疫表型及其与预后的关系。
采用CD34/SSC设门三色流式细胞术分析,对106例成年急性白血病患者进行免疫表型分析。
71例急性髓系白血病(AML)患者表达的抗原主要为CD13、CD33、HLA-DR、CD34和CD117。23.9%的成年AML患者存在淋巴系抗原表达,15.5%的AML患者表达CD56抗原。29例急性淋巴细胞白血病(ALL)患者表达的抗原主要为HLA-DR、CD10、CD19、CD34和CD7,其中34.5%的患者髓系抗原表达呈阳性。化疗后有淋巴系抗原表达的AML患者完全缓解(CR)率低于无淋巴系抗原表达的AML患者(52.9%对77.8%,P<0.05),ALL患者髓系抗原表达对CR无显著影响(70.0%对94.7%,P>0.05)。有CD56抗原表达的AML患者CR率低于无CD56表达的AML患者(36.4%对78.3%,P<0.025),CD34+AML患者的CR率低于CD34-AML患者(56.0%对80.4%,P<0.05)。
CD45/SSC设门可消除正常细胞的干扰,使免疫表型分析结果更可靠。成年AML患者中CD56+、CD34+、淋巴系抗原表达且CR率较低,常提示预后不良。